

REMARKS

After entry of this amendment, claims 1-8 and 11-24 and 31 are pending. Claims 9, and 25-30 have been withdrawn from consideration due to a revised restriction requirement. Applicants hereby elect the corrected Group I for claims 1-8 and 11-24, without traverse.

The specification has been amended to recite the SEQ ID NOs of the sequences recited therein.

Figure 1 has been amended to insert SEQ ID NOs.

Claim 31 was added to recite the method of claim 24 wherein the target simple sequence repeat, modified oligonucleotide, LNA and target source are as specified. Support is in the specification on pages 17-18.

No new matter has been added by these amendments.

Sequence Listing

The Notice to Comply states a Sequence Listing is required for this application. Submitted herewith is a Sequence Listing. Also, the Specification has been amended to insert the SEQ ID NOs in the text of the application.

Statement


Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Applicants respectfully reply that any fees were requested to be charged to the deposit account of Syngenta Biotechnology Inc. and that the present response provides a list of claims thought to read on the elected species.

Please charge any additional fees or credit any overpayment to Deposit

Account No. 50-1744 (in the name of Syngenta Biotechnology Inc.).

Respectfully Submitted,


Mary S. Kakefuda
Reg. No. 39,245
Attorney for Applicants

Syngenta Biotechnology, Inc.
P.O. Box 12257
3054 Cornwallis Road
Research Triangle Park, NC 27709-2257

Tel: 919-765-5071
Fax: 919-541-8689

Date: April 19, 2004